Promising combo for breast cancer falls short: trial ends early
NCT ID NCT04113863
First seen Dec 26, 2025 · Last updated Apr 29, 2026 · Updated 19 times
Summary
This study tested whether adding ATRA (a vitamin A derivative) to the standard hormone therapy anastrozole could shrink tumors in postmenopausal women with a common type of early breast cancer (HR+/HER2-). The goal was to see if the combination worked better than anastrozole alone before surgery. However, the trial was stopped early, so the results are limited and no clear conclusions can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM FEMALE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Papa Giovanni XXIII
Bergamo, 24127, Italy
-
Ospedale Santa Maria della Misericordia di Udine
Udine, UD, 33100, Italy
Conditions
Explore the condition pages connected to this study.